IAVI and Serum Institute of India to develop and manufacture globally affordable and accessible antibody products for HIV

Collaboration to develop optimal combination of HIV-specific antibodies and ensure that cost is not a barrier to access The International AIDS Vaccine Initiative (IAVI) and Serum Institute of India, the world’s largest vaccine manufacturer, announced a strategic partnership to develop and manufacture affordable and accessible monoclonal antibody products for HIV and other global health challenges. “IAVI is committed to translating scientific innovation into public health solutions, and we are collaborating with Serum Institute to enable global access to broadly neutralizing monoclonal antibodies (bNAbs) against HIV, if they are proven effective at preventing HIV infection. Through this partnership, we will work to pioneer a viable and sustainable pathway toward accessible, low-cost, antibody-based products for HIV, which if successful, may also be applied more broadly to innovative monoclonal antibody therapeutics targeting other disease areas,” said Mark Feinberg, M.D., Ph.D., president and CEO, IAVI. “We have a proven record of developing and delivering vaccines and pharmaceutical...